Koji Matsuo1,2, Rachel S Mandelbaum3, Hiroko Machida4, Kosuke Yoshihara5, Shinya Matsuzaki3, Maximilian Klar6, Franco M Muggia7, Lynda D Roman3,8, Jason D Wright9. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, 2020 Zonal Avenue, IRD 520, Los Angeles, CA, 90033, USA. koji.matsuo@med.usc.edu. 2. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. koji.matsuo@med.usc.edu. 3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, 2020 Zonal Avenue, IRD 520, Los Angeles, CA, 90033, USA. 4. Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan. 5. Department of Obstetrics and Gynecology, Niigata University School of Medicine, Niigata, Japan. 6. Department of Obstetrics and Gynecology, University of Freiburg, Freiburg, Germany. 7. Division of Medical Oncology, Department of Medicine, New York University, New York, NY, USA. 8. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. 9. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Abstract
PURPOSE: To examine trends, characteristics and outcomes of women who develop both ovarian and breast cancers. METHODS: This is a retrospective study examining the Surveillance, Epidemiology, and End Results Program from 1973 to 2013. Among ovarian cancer (n = 133,149) and breast cancer (n = 1,143,219) cohorts, women with both diagnoses were identified and temporal trends, tumor characteristics and survival were examined. RESULTS: There were 6446 women with both malignancies, representing 4.8% of the ovarian cancer cohort and 0.6% of the breast cancer cohort. Women with ovarian cancer who had secondary breast cancer were younger than those without secondary breast cancer early in the study period (52.3 versus 59.2 in 1973) but older in more recent years (68.5 versus 62.1 in 2013, P < 0.001). The number of breast cancer survivors who developed postcedent ovarian cancer decreased from 1.5 to 0.2% from 1979 to 2008 (relative risk reduction 90.0%, P < 0.05). Similarly, the number of ovarian cancer survivors who developed postcedent breast cancer decreased from 7.2 to 2.0% from 1973 to 2008 (relative risk reduction 72.4%, P < 0.05). Tumor characteristics were more likely to be favorable in women with ovarian cancer who developed postcedent breast cancer but unfavorable in those who had antecedent breast cancer (all, P < 0.05). Women with ovarian cancer who had secondary breast cancer had superior cause-specific survival compared to those who did not develop breast cancer regardless of breast cancer timing (P < 0.05). CONCLUSION: Our study demonstrated that the demographics of women who develop breast cancer and ovarian cancer have changed over time and diagnosis of secondary breast cancer after ovarian cancer has decreased.
PURPOSE: To examine trends, characteristics and outcomes of women who develop both ovarian and breast cancers. METHODS: This is a retrospective study examining the Surveillance, Epidemiology, and End Results Program from 1973 to 2013. Among ovarian cancer (n = 133,149) and breast cancer (n = 1,143,219) cohorts, women with both diagnoses were identified and temporal trends, tumor characteristics and survival were examined. RESULTS: There were 6446 women with both malignancies, representing 4.8% of the ovarian cancer cohort and 0.6% of the breast cancer cohort. Women with ovarian cancer who had secondary breast cancer were younger than those without secondary breast cancer early in the study period (52.3 versus 59.2 in 1973) but older in more recent years (68.5 versus 62.1 in 2013, P < 0.001). The number of breast cancer survivors who developed postcedent ovarian cancer decreased from 1.5 to 0.2% from 1979 to 2008 (relative risk reduction 90.0%, P < 0.05). Similarly, the number of ovarian cancer survivors who developed postcedent breast cancer decreased from 7.2 to 2.0% from 1973 to 2008 (relative risk reduction 72.4%, P < 0.05). Tumor characteristics were more likely to be favorable in women with ovarian cancer who developed postcedent breast cancer but unfavorable in those who had antecedent breast cancer (all, P < 0.05). Women with ovarian cancer who had secondary breast cancer had superior cause-specific survival compared to those who did not develop breast cancer regardless of breast cancer timing (P < 0.05). CONCLUSION: Our study demonstrated that the demographics of women who develop breast cancer and ovarian cancer have changed over time and diagnosis of secondary breast cancer after ovarian cancer has decreased.
Entities:
Keywords:
Breast cancer; Ovarian cancer; Secondary cancer; Survival; Trend
Authors: Koji Matsuo; Rachel S Mandelbaum; Hiroko Machida; Kosuke Yoshihara; Franco M Muggia; Lynda D Roman; Jason D Wright Journal: Gynecol Oncol Date: 2019-05-23 Impact factor: 5.482
Authors: J Boyd; Y Sonoda; M G Federici; F Bogomolniy; E Rhei; D L Maresco; P E Saigo; L A Almadrones; R R Barakat; C L Brown; D S Chi; J P Curtin; E A Poynor; W J Hoskins Journal: JAMA Date: 2000-05-03 Impact factor: 56.272
Authors: Helga Primas; Regina Kroiss; Karin Kalteis; Christine Rappaport; Daniela Muhr; Christian Primas; Ernst Kubista; Reinhard Horvat; Peter Oefner; Christian Singer; Teresa Wagner And The Austrian Hereditary Breast And Ovarian Cancer Group Journal: Eur J Cancer Prev Date: 2012-03 Impact factor: 2.497
Authors: Koji Matsuo; Rachel S Mandelbaum; Hiroko Machida; Kosuke Yoshihara; Franco M Muggia; Lynda D Roman; Jason D Wright Journal: J Clin Med Date: 2019-05-20 Impact factor: 4.241
Authors: Zhuo Chen; Katherine Kolor; Scott D Grosse; Juan L Rodriguez; Julie A Lynch; Ridgely Fisk Green; W David Dotson; M Scott Bowen; Muin J Khoury Journal: Genet Med Date: 2017-09-21 Impact factor: 8.822